T2 Biosystems, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From T2 Biosystems, Inc.
Citing the pandemic, the US Centers for Medicare & Medicaid Services (CMS) discounted 2020 data in reviewing renewals for New Technology Add-On Payment (NTAP) status and granted extensions through 30 September to 13 NTAP products.
Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.
Marc Jones is taking on the dual role of chief operating officer and chief financial officer at UK point-of-care diagnostics firm Atlas Genetics.
Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.
- In Vitro Diagnostics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.